What is Oxford BioTherapeutics's contact information?

Oxford BioTherapeutics's contact information: +441235861770.

How many employees does Oxford BioTherapeutics have?

Oxford BioTherapeutics has 53 employees.

What industry does Oxford BioTherapeutics belong to?

Oxford BioTherapeutics is in the industry of: Pharmaceuticals, Biotechnology, Healthcare.

What are Oxford BioTherapeutics's official social media profiles?

Oxford BioTherapeutics Linkedin Page Oxford BioTherapeutics Twitter Page

What tech stack does Oxford BioTherapeutics use?

Some of the popular technologies that Oxford BioTherapeutics uses are: Cloudflare Bot Management.

What are Oxford BioTherapeutics's office addresses?

Oxford BioTherapeutics has 6 known office addresses: 5941 Optical Court, San Jose, CA 95138, USA The Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE, UK The Schrodinger Building, Oxford Science Park, Suite A, Second Floor, GB San Jose Biocenter, 5941 Optical Court, US Morristown, New Jersey, US The Schrodinger Building, Oxford Science Park, Suite A, Second Floor, Oxford, Ox4 4ge, Gb.

What is Oxford BioTherapeutics's estimated annual revenue?

Oxford BioTherapeutics's revenue is $6,193,000

What is Oxford BioTherapeutics's open headcount?

Oxford BioTherapeutics has 3 job postings.

What is the number of ad campaigns for Oxford BioTherapeutics?

Oxford BioTherapeutics has no advertisements yet.

What is the number of recent news articles about Oxford BioTherapeutics?

Oxford BioTherapeutics has one news article.

Oxford BioTherapeutics - Pubrio Company Profile & Intent

Oxford BioTherapeutics

United Kingdom · Biotechnology

Pharmaceuticals

Biotechnology

Healthcare

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT's proprietary OGAP® target discovery platform is based on one of the world's largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company's pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).